GALT Galectin Therapeutics Inc.
Debt Financing ·
The new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance.
We have not published a story on Galectin Therapeutics yet. When there is news, it will appear here.
Galectin Therapeutics is a clinical stage biopharmaceutical company developing therapies for fibrotic disease, cancer and selected other diseases. Its drug candidates are carbohydrate-based compounds that bind and inhibit galectin proteins, particularly galectin-3. Its lead galectin-3 inhibitor, belapectin (GR-MD-02), is being studied for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. The NAVIGATE trial, a Phase 2b/3 study of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis, randomized 357 patients by February 2023. In December 2024 the company reported top-line results: in the intent-to-treat population (N=355), the incidence of varices was reduced by 43.2% in the belapectin 2 mg/kg group versus placebo, but the composite endpoint did not reach statistical significance. In the per-protocol population (n=287), the incidence of varices was reduced by 49.3%. The company has also filed a new IND with the FDA for belapectin in combination with a PD-1 inhibitor for advanced or metastatic head and neck cancer, and says the proposed Phase 2 trial depends on the timing of financing. Galectin also operates Galectin Sciences LLC, a majority-owned joint venture developing small molecule galectin-3 inhibitors.
| Product or program | What it is | Stage |
|---|---|---|
| Belapectin (GR-MD-02) | Galectin-3 inhibitor studied for esophageal varices prevention in MASH cirrhosis | Phase 2b/3 NAVIGATE trial; top-line results reported December 2024 |
| Belapectin in head and neck cancer | Belapectin combined with a checkpoint (PD-1) inhibitor for advanced or metastatic head and neck cancer | Study May Proceed letter received; proposed Phase 2 depends on financing |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $14.3 million | $36.6 million |
| Net income (loss) | -$30.8 million | -$47.0 million |
| Cash from operations | -$23.9 million | -$41.8 million |
| Cash and equivalents | $17.7 million | $15.1 million |
Galectin Therapeutics Inc. trades under the ticker GALT on NASDAQ.
Galectin Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PHPN.
The SEC Central Index Key (CIK) for Galectin Therapeutics Inc. is 1133416. Its filings are on SEC EDGAR.
100,849,644 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Galectin Therapeutics Inc. under United States.
Our directory classifies Galectin Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Galectin Therapeutics Inc. is US3632252025.
aibio.space lists Galectin Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Galectin Therapeutics is a clinical stage biopharmaceutical company developing therapies for fibrotic disease, cancer and selected other diseases. Its drug candidates are carbohydrate-based compounds that bind and inhibit galectin proteins, particularly galectin-3.
Belapectin (GR-MD-02): Galectin-3 inhibitor studied for esophageal varices prevention in MASH cirrhosis Stage: Phase 2b/3 NAVIGATE trial; top-line results reported December 2024.
Belapectin in head and neck cancer: Belapectin combined with a checkpoint (PD-1) inhibitor for advanced or metastatic head and neck cancer Stage: Study May Proceed letter received; proposed Phase 2 depends on financing.
Galectin Therapeutics Inc. reported a net loss of $30.8 million for the fiscal year ended Dec 31, 2025, and used $23.9 million of cash in operations, per its annual report to the SEC.
$14.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$13.3 million in cash at Jun 30, 2026, per its 10-Q.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio